Oncology Voice Network
Join the Oncology Voice Network. Join for Free
The Power of Non Traditional KOL Engagement
Nontraditional KOL engagement Medical Science Liaisons strategies personalized communication in healthcare compliance in KOL interactions empathy in healthcare relationships

The Power of Non Traditional KOL Engagement

  • Apr 22nd 2025
  • 29 mins
  • E251

Share This Article

Summary

In this episode, Tom Caravela is joined by Lindsey Harrer to discuss the power of non traditional Key Opinion Leader (KOL) engagement for Medical Science Liaisons (MSLs). They explore the differences in KOL interactions, strategies for aligning MSL objectives with KOL needs, and the importance of personalized communication. The conversation highlights compliance challenges in nontraditional KOL engagement and its future potential. Lindsey shares insights on applying nontraditional approaches in interviews and MSL strategies, emphasizing the importance of empathy in connecting with healthcare professionals on a human level. The episode concludes with closing remarks and expressions of gratitude.

Key Points

  • Nontraditional KOL engagement focuses on understanding healthcare providers' challenges and needs from a deeply human perspective.
  • Genuine curiosity and active listening are essential in building meaningful relationships and creating tailored solutions for healthcare providers.
  • Partnering with compliance and legal teams from the outset ensures innovative initiatives are implemented effectively and within regulatory guidelines.

Click for Source
Nontraditional KOL engagement, Medical Science Liaisons strategies, personalized communication in healthcare, compliance in KOL interactions, empathy in healthcare relationships

Related Topics

Explore the Ecosystem

Meet Our Innovation Partners

You May Also Like

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Jul 11th • 10 mins • read
Article
The Oncology Data Network (ODN): Methodology, Challenges, and Achievements
OVN Avatar Ashley Woolmore , Dirk Arnold , Jean‐Yves Blay , Christian Buske , Alfredo Carrato , Winald Gerritsen , Marc Peeters , Jesus Garcia‐Foncillas , David Kerr

The Oncology Data Network (ODN): Methodology, Challenges, and Achievements

May 21st • 8 mins • read
Article
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
OVN Avatar Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

May 3rd • 10 mins • read
Article
Loose Regulatory Standards Portend a New Era of Imprecision Oncology
OVN Avatar Ali Raza Khaki

Loose Regulatory Standards Portend a New Era of Imprecision Oncology

Dec 1st • 4 mins • read
Article
Expert perspectives live from ASCO® 2025
Partner Avatar iNIZIO

Expert perspectives live from ASCO® 2025

Jul 2nd • 1 min • read
Article
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
OVN Avatar Nidal Al-Huniti, Yan Feng, Jingyu (Jerry) Yu, Zheng Lu, Mario Nagase, Diansong Zhou, Jennifer Sheng

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

Jun 26th • 18 mins • read

Explore OVN

Articles Expert-written insights
Browse Ecosystem Oncology focus areas
OVN Podcast Flagship show
Community Why join OVN